# MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 1988 · $249,684

## Abstract

Animal models have been developed in which adoptively transferred immune T
cells can reproducibly mediate an in vivo therapeutic effect against
disseminated leukemia.  The prerequisites for success have been extensively
investigated, since these models represent prototypes for what might be
achievable with appropriately selected and amplified tumor-reactive
autologous lymphocytes obtained from a tumor-bearing host.  This
application proposes to utilize monoclonal antibodies specific for
lymphocyte subpopulations and purified cytokines to learn how the immune
system might be modulated to generate an effective anti-tumor response for
the purpose of treating established metastatic solid tumors and
disseminated leukemias.

The specific aims are:  1) To examine the mechanism(s) by which
non-cytolytic T cells promote the eradication of disseminated leukemia by
examining the importance of B cell antibody production, NK activity, and
tumoricidal macrophages; 2) To determine the role of secreted
Gamma-interferon in the therapeutic effect of non0cytolytic T cells and to
assess whether other macrophage activating factors potentially contribute
to therapeutic activity; 3) To assess whether the demonstrated efficacy of
purified CTL in therapy of disseminated leukemia reflects only direct
cytolysis of tumor cells or is dependent on the activation and
participation of tumoricidal macrophages; 4) To determine whether a major
obstacle to adoptive therapy of advanced disseminated leukemia is the
induction of suppressor T cells in the donor population after cell
transfer; 5) To determine whether the principles for eradicating a highly
antigenic disseminated leukemia can be applied to the therapy of weakly
antigenic solid tumor metastases; 6) To develop models for allogeneic
adoptive therapy and determine whether minor histocompatibility antigens on
tumors can serve as appropriate targets for immunologic attack.

## Key facts

- **NIH application ID:** 3171019
- **Project number:** 5R01CA033084-06
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **SAM.gov UEI:** HD1WMN6945W6
- **Principal Investigator:** PHILIP D GREENBERG
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $249,684
- **Award type:** 5
- **Project period:** 1982-08-01 → 1991-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171019

## Citation

> US National Institutes of Health, RePORTER application 3171019, MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY (5R01CA033084-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171019. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*